Home Monitoring in New Jersey

AdhereTech (Digital Medical Technologies) develops Aidia, an award-winning smart medication adherence system designed to improve patient medication compliance and retention. The platform consists of the Aidia Smart Bottle with integrated smart cap technology that fits standard prescription bottle sizes, coupled with a cloud-based analytics platform delivering real-time patient-level insights. The system operates via built-in cellular connectivity with no patient app requirement, using gentle reminders and interventions when doses are missed. Clinical evidence demonstrates 50%+ improvement in patient retention within the first year and consistent patient satisfaction scores exceeding 95%. The solution addresses the $290B annual cost of medication non-adherence to the US healthcare system. Aidia serves three primary markets: pharmaceutical manufacturers seeking to improve drug commercialization and patient persistence; clinical trial sponsors requiring enhanced protocol compliance; and healthcare systems and pharmacies optimizing patient outcomes. The device maintains medication stability while providing behavioral intervention through visual cues (blue light) and text message reminders. Regulatory credentials and specific FDA clearance status not detailed on primary pages. The company has received multiple design and innovation awards including recognition from Fast Company, Good Design Award, and A Design Award.

Curio Digital Therapeutics develops AI-driven digital-first behavioral health solutions specifically for women's mental health across fertility, pregnancy, postpartum, and menopause life stages. The company offers Prescription Digital Therapeutic (PDT) products FDA-authorized for postpartum depression treatment, complemented by coaching and therapist-supported programs. Core offerings include MamaLift and MamaLift Plus, on-demand digital therapy platforms featuring evidence-based cognitive behavioral therapy (CBT) lessons, health trackers, and live health coach support. Curio-I is an AI-powered predictive platform for early identification and risk stratification of mental health disorders affecting women. All products are validated through clinical trials, with seven published studies demonstrating clinical efficacy. The platform operates on cloud-first, mobile-first architecture enabling anytime, anywhere access. Early adopters and partners include Mount Sinai Health System, Columbia University, and various health plans. The company has received recognition from Business Insider, BioNJ, and innovation awards including Point32 and MassChallenge. Product outcomes show 2 of 3 women achieving symptom improvement below depression thresholds, 70% user referral rates, and 5:1 return on investment metrics.

Rescue Shot Case manufactures and distributes protective carrying cases for emergency medications and life-saving devices. The company specializes in hard cases and soft bags designed to store and protect naloxone (Narcan) opioid overdose kits, epinephrine auto-injectors (EpiPen), and Auvi-Q devices. Product offerings include the Professional Naloxone Overdose Kit Case (hard case, from $17.99), Naloxone Opioid Overdose Kit Bag (soft bag, $7.99), and Tactical Molle Naloxone Kit Bag Case ($19.99). The company also offers an AED Overdose Co-Location Kit, integrating naloxone storage with automated external defibrillator positioning. Rescue Shot Case serves consumers, first responders, community organizations, schools, and government agencies through both retail and bulk/government procurement channels. The company emphasizes always-visible, always-ready emergency medicine accessibility. Custom case solutions are available for specialized applications. The business model combines direct e-commerce with institutional bulk ordering programs for government and public health initiatives.

Enterix, Inc. is a biotechnology company specializing in fecal immunochemical tests (FIT) for colorectal cancer screening and detection of lower gastrointestinal bleeding disorders. Founded in 1997 and based in Edison, NJ, the company emphasizes non-invasive, patient-friendly testing with simple at-home sample collection. Core products include InSure FIT (lab-based test for occult blood detection), InSure Quik FIT (point-of-care physician office version), and InSure One (at-home test using toilet bowl water collection via brush). All products support annual colorectal cancer screening recommendations aligned with American Cancer Society guidelines (screening starting at age 45). Enterix operates internationally with FDA clearance, CLIA waiver certification, and TGA licensing. Distribution partnerships include Quest Diagnostics and HemoCue, Inc., enabling availability through healthcare providers, pharmacies, and direct-to-consumer channels. The company prioritizes screening adherence through elimination of stool handling and sample preparation requirements.

Sensiband is an at-home metal allergy testing kit designed to identify skin sensitivity to metals commonly used in medical implants and procedures before surgical implantation. The product consists of seven metal test discs inserted into a silicone wristband that patients wear for 7+ consecutive days to detect contact dermatitis reactions. Founded by orthopedic surgeons, Sensiband addresses a significant clinical gap: patients undergoing joint replacements, dental implants, cardiac devices, arterial stents, and orthopedic hardware often experience post-operative complications that may stem from undiagnosed metal allergies. By enabling pre-procedure testing similar to patch testing in dermatology, Sensiband helps patients and clinicians make informed material selections, potentially reducing adverse outcomes and improving surgical success rates. The company markets direct-to-consumer kits targeting patients preparing for orthopedic, cardiac, and dental procedures.